linjc16/ctgov huggingface dataset:
Operant Conditioning of Reflex Pathways to Improve Walking in Individuals Post-stroke

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the changes in reflex pathways in the paretic ankle plantarflexors in individuals with post-stroke hemiparesis using operant conditioning. We are recruiting 5 individuals with chronic post-stroke hemiparesis with foot drop in the affected leg to participate in the reflex training procedure. The study involves 40 visits with a total study duration of about 4 months.

Official Title
-----------------
Operant Conditioning of Reflex Pathways to Improve Walking in Individuals Post-stroke

Conditions
-----------------
Stroke, Post-stroke Hemiparesis, Foot Drop

Intervention / Treatment
-----------------
* Behavioral: Operant conditioning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 6 months following a single, unilateral stroke, resulting in hemiparesis. Ambulatory with or without assistive device, but must demonstrate a gait deficit which is indicative of foot drop from reduced activation of the tibialis anterior muscle. Able to follow verbal directions. Able to see icons on computer monitor (with or without corrective lenses) from at least 4 feet away. All subjects will be adults at least 18 years old. Know history and current medication management for lower limb spasticity, if any. Exclusion Criteria: No history of ear disease or balance problems outside of those caused by the stroke. Cerebellar stroke No other neurological disease or injuries other than the stroke affecting the use of the legs and/or walking.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Reciprocal inhibition up conditioning<br>Each participant completes 6 baseline sessions and 30 up conditioning sessions. In the 30 conditioning sessions, the magnitude of reciprocal inhibition in the paretic leg of participants post-stroke will be up conditioned. | Behavioral: Operant conditioning<br>* In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in magnitude of reciprocal inhibition |  | Before training Baseline, after completion of 30 training sessions, and 1 month after the completion of intervention |
Observational Study on the Improvement of Dry Eye Syndrome, Treatment Satisfaction, and Intraocular Tolerance With Diquasol Eye Drops

Study Overview
=================
Brief Summary
-----------------
This study is to verify the efficacy and safety in the treatment of dry eye syndrome in patients prescribed with Diquasol eye drops as a monotherapy, or in combination with Hyaluron eye drops, or in combination with Hyaluronmax eye drops.

Detailed Description
-----------------
This study is to observe the prescription patterns in routine clinical practice and assess the changes in dry eye symptoms, treatment satisfaction, and intraocular tolerance over a 12-week period in patients prescribed with Diquasol eye drops as a monotherapy or in combination with Hyaluron eye drops or Hyaluronmax eye drops for the treatment of dry eye syndrome.

Official Title
-----------------
Observational Study on the Improvement of Dry Eye Syndrome, Treatment Satisfaction, and Intraocular Tolerance With Diquasol Eye Drops and Hyaluron/Hyaluronmax Eye Drops in Patients Over 19 Years Old With Dry Eye Syndrome

Conditions
-----------------
Dry Eye Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults aged 19 years and older Patients with dry eye syndrome with TBUT of 10 or less Individuals scheduled to receive either Diquasol eye drops as a monotherapy or a combination therapy of Diquasol eye drops with Hyaluron eye drops or Diquasol eye drops with Hyaluronmax eye drops, based on clinical judgment for the treatment of dry eye syndrome Individuals who have voluntarily provided written consent for participation in this study Exclusion Criteria: Pregnant or lactating women Individuals contraindicated according to the approval conditions of Diquasol eye drops, Hyaluron eye drops, and Hyaluronmax eye drops Cases where the principal investigator or study personnel deem the individual unsuitable for participation in this clinical study

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Assessment Variables | Changes in Tear Break-Up Time (TBUT) after 12 weeks according to each group, including monotherapy with Diquasol eye drops, combination therapy with Diquasol eye drops and Hyaluron eye drops, and combination therapy with Diquasol eye drops and Hyaluronmax eye drops. | after 12 weeks of prescription for Diquasol eye drops and Hyaluron/Hyaluronmax eye drops compared to baseline |
Incidence of Refeeding Syndrome in Consecutively Admitted Patients

Study Overview
=================
Brief Summary
-----------------
The incidence and main risk-factors analyzed in consecutive in-patients in the departments og gastroenterology and ear-nose and throat diseases (cancer in radiation therapy)

Detailed Description
-----------------
Patients with either parenteral- or tube feeding enter the study to assure sufficient nutrition. During hospitalization patients were monitored with daily blood samples and clinical evaluation of symptoms in addition to the coverage of energy and protein in percent of estimated needs. Refeeding phenomenon was defined as a decrease in plasma phosphate after the initiation of nutrition. Refeeding syndrome as refeeding phenomenon and one or more relevant symptoms in addition (hypotension, cardiac arrhythmia, edema, confusion)

Official Title
-----------------
Refeeding Syndrome - Incidence and Risk Factors: An Observational Study on Patients With G-I Disease and Head-neck Cancer

Conditions
-----------------
Refeeding Syndrome, Starvation, Phosphate Deficiency

Intervention / Treatment
-----------------
* Other: observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: planned tube- or parenteral nutrition (complete or supplementary) > 18 years written consent Exclusion Criteria: Renal insufficiency (p-creatinine >200 micromol/l) Lack of ability to communicate (registration of nutritional intake etc)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gastroenterological<br>Consecutive admissions - n= 43 - 34 operated (79%) - 10 patients acutely admitted Diseases in Esophagus (8), gastric cavity (8), pancreas (7), colon/rectum (8), bile (4), small intestine (3), IBD (5) No interventions in the treatments, just observation | Other: observation<br>* no intervention<br>|
| head and neck cancer<br>Consecutive admissions - n=8 - 7 radiation therapy - 1 operated Locations: 2 Larynx, 1 oro-pharynx, 4 tonsillar, 1 tung No interventions in the treatments, just observation | Other: observation<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Refeeding syndrome | No. patients with decrease in plasma phosphate + clinical symptoms | 1 week after start of nutrition | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Refeeding phenomenon | No. patients with decrease in plasma phosphate after start of nutrition | 1 week after start of nutrition |
Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State

Study Overview
=================
Brief Summary
-----------------
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01(5/1000 mg x1 tablets) at fed state.

Official Title
-----------------
An Open Label, Randomized, Single Dose, Cross-over ,Two-group Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 5/1000mg in Healthy Subjects at Fed State

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: DA-1229_01 5/1000mg (Before)
* Drug: DA-1229_01 5/1000mg (After)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusive Criteria: Healthy Volunteers BMI between 18 and 30 kg/m2 Body weight : Male≥50kg, Female≥45kg Exclusion Criteria: Allergy or Drug hypersensitivity Clinically significant Medical History

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequence A(Before→ After)<br> | Drug: DA-1229_01 5/1000mg (Before)<br>* single dose administration (one tablet once a day)<br>Drug: DA-1229_01 5/1000mg (After)<br>* single dose administration (one tablet once a day)<br>|
| Experimental: Sequence B(After→ Before)<br> | Drug: DA-1229_01 5/1000mg (Before)<br>* single dose administration (one tablet once a day)<br>Drug: DA-1229_01 5/1000mg (After)<br>* single dose administration (one tablet once a day)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCt | area under the curve | pre-dose 48 hours post-dose | 
| Cmax | maximum plasma concentration | pre-dose 48 hours post-dose |
Assessment of the Ankle Joint Axis Using a Long Ankle View Radiograph

Study Overview
=================
Brief Summary
-----------------
The study is a reliability (reproducibility) study on a single measurement procedure. Reliability (reproducibility) will be assessed by repeating the whole measurement procedure twice. The measurement procedure studied is the generation of a long ankle view image based on a radiographic assessment followed by a manual assessment of the medial-distal tibial angle.

Detailed Description
-----------------
The study is a reliability (reproducibility) study on a single measurement procedure. Reliability (reproducibility) will be assessed by repeating the whole measurement procedure twice. The measurement procedure studied is the generation of a long ankle view image based on a radiographic assessment followed by a manual assessment of the medial-distal tibial angle (MDTA). In order to assess the value of different assessment methods of the MDTA, several variants will be considered, which are all applied to the same long ankle view image. To determine the intra- and interrater reliability of the manual assessment, this assessment will be done twice by different observers (one doctoral student, one radiologist) and repeated within each observer.

Official Title
-----------------
Assessment of the Ankle Joint Axis Using a Long Ankle View Radiograph

Conditions
-----------------
X-ray

Intervention / Treatment
-----------------
* Device: Radiographic assessment of the medial-distal tibial angle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Clinical indication for a radiographic assessment of the lower half of one leg Age above 20 Exclusion Criteria: Previous bony procedures (surgery), fractures or anomalies of the lower leg, which does not allow a reliable assessment of the MDTA Symptomatic or clinically obvious malalignment at any level of the lower extremity Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All patients<br>All patients | Device: Radiographic assessment of the medial-distal tibial angle<br>* A long ankle view will be generated within a standard radiographic assessment and the medial-distal tibial angle will be assessed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| medial-distal tibial angle | The angle is determined based on determining the mechanical axis and the angle axis. | Day 1 (There is only one single day of contact for each patient) |
Identification and Verification of Neutrophil Extracellular Trap Net Related Markers in Acute-on-chronic Liver Failure

Study Overview
=================
Brief Summary
-----------------
Acute-on-chronic liver failure (ACLF) refers to the acute deterioration of liver function in patients with chronic liver disease. Neutrophils are a major component of the innate immune system, and previous studies have revealed enhanced production of neutrophil extracellular traps (NETs) in ACLF. However, there is still a lack of systematic research on the correlation between NETs and the prognosis of ACLF. We screened NETs related biomarkers through bioinformatics analysis, which play an important role in the diagnosis of ACLF. This study will explore whether these NETs related biomarkers also play an important role in the prognosis of ACLF and further investigate their role in the pathogenesis of ACLF.

Official Title
-----------------
Identification and Verification of Neutrophil Extracellular Trap Net Related Markers in Acute-on-chronic Liver Failure

Conditions
-----------------
Acute-On-Chronic Liver Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients who meet the diagnostic criteria of Chinese Group on the Study of Severe Hepatitis B (COSSH) for acute-on-chronic liver failure Exclusion Criteria: Age greater than 75 years old liver cancer previous liver transplantation other serious extrahepatic organ diseases uncontrolled bacterial infections.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ACLF<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality | mortality of patients with ACLF | 30 days | 
| mortality | mortality of patients with ACLF | 90 days | 
| mortality | mortality of patients with ACLF | half a year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neutrophil extracellular traps
Subjects Perceived as Embarrassing During a Consultation in General Medical Practice

Study Overview
=================
Brief Summary
-----------------
Optimal medical care requires transparency and honesty. However, it is not always easy to address some issues that may be considered too personal, intimate or taboo, such as mental health, sexuality, addiction and death. Patients' approach to these issues may be influenced by the profile of their general practitioner, or by the atmosphere of the consultation. This retention of information by the patient, whether voluntary or not, can lead to adverse events related to care due to a misunderstanding between doctor and patient.

Detailed Description
-----------------
The main objective is to describe the proportion of patients limiting the subjects addressed during a general medicine consultation by gene, modesty and/or fear of judgment The secondary objective is to study the factors associated with limitation of subjects addressed by patient by gene, modesty and/or fear of judgment during a general medicine consultation.

Official Title
-----------------
Subjects Perceived as Embarrassing During a Consultation in General Medical Practice

Conditions
-----------------
General Practice

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years of age Agreeing to take part in the study Exclusion Criteria: Minors Protected by law (guardianship, curatorship, safeguard of justice) Refusing to take part in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| people over the age of 18<br>people over the age of 18. | Other: Data collection<br>* Data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| limitation of subjects addressed by gene, modesty and/or fear of judgment | Proportion of patients who have ever restricted the subjects discussed during a general medical consultation by gene, modesty and/or fear of judgment | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
general medical consultation, gene, modesty, fear of judgment
Inflammatory Bowel Disease and Atherosclerosis Development

Study Overview
=================
Brief Summary
-----------------
The study will show the influence of inflammatory bowel disease on the risk of development of atherosclerosis

Official Title
-----------------
Inflammatory Bowel Disease and Atherosclerosis Development

Conditions
-----------------
Inflammatory Bowel Diseases, Cardiovascular Diseases, Inflammation, Arterial Stiffness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inflammatory bowel disease Signed informed consent Exclusion Criteria: Pregnancy Other conditions affecting the prognosis Psychiatric disorders affecting the participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ulcerative colitis<br> | |
| Crohn disease<br> | |
| Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intima-media thickness | Intima-media thickness | 1 year | 
| Pulse wave velocity | Pulse wave velocity | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality |  | 1 year | 
| Cardiovascular mortality |  | 1 year | 
| Hospitalisation due to cardiovascular disease |  | 1 year |
A Study to Learn About the Study Medicine - Precedex in Children From Japan.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to look at the safety of Precedex when it was used to calm children at procedures or tests under actual medical practice in Japan. This study is seeking for children who are 1 month to less than 18 years old. The patients are planned to be looked over: From the time of patient check before receiving Precedex To 1 hour after the completion or stop of using Precedex.

Official Title
-----------------
Precedex Intravenous Solution Special Investigation (Sedation of Non-intubated Pediatric Patients for Non-invasive Procedures and Tests)

Conditions
-----------------
Sedation

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients (1 month to < 18 years old) administered Precedex for sedation of non-intubated pediatric patients for non-invasive procedures and tests Exclusion Criteria: No exclusion criteria is set out in this study.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dexmedetomidine Hydrochloride<br>Pediatric patients (1 month to < 18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation of non-intubated pediatric patients for non-invasive procedures and tests | Drug: Dexmedetomidine Hydrochloride<br>* <Sedation of non-invasive procedures and tests without intubation in pediatrics> For children aged 2 years or older, the usual dosage of dexmedetomidine is 12 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose). For children aged 1 month to < 2 years old, the usual dosage of dexmedetomidine is 9 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose). The infusion rate should be reduced according to patient's condition.<br>* Other names: Precedex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with adverse drug reactions (ADRs) |  | From the time of patient assessment before the start of administration of Precedex to 1 hour after the completion or discontinuation of administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Precedex;, Dexmedetomidine Hydrochloride;, Sedation;, non-intubated;, pediatric;, non-invasive procedures and tests